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Abstract: Opioids are highly addictive substances with a relapse rate of over 90%. While preclinical
models of chronic opioid exposure exist for studying opioid dependence, none recapitulate the
relapses observed in human opioid addiction. The mechanisms associated with opioid dependence,
the accompanying withdrawal symptoms, and the relapses that are often observed months or
years after opioid dependence are poorly understood. Therefore, we developed a novel model of
chronic opioid exposure whereby the level of administration is self-directed with periods of behavior
acquisition, maintenance, and then extinction alternating with reinstatement. This profile arguably
mirrors that seen in humans, with initial opioid use followed by alternating periods of abstinence
and relapse. Recent evidence suggests that dietary interventions that reduce inflammation, including
omega-3 polyunsaturated fatty acids (n-3 PUFAs), may reduce substance misuse liability. Using the
self-directed intake model, we characterize the observed profile of opioid use and demonstrate that an
n-3-PUFA-enriched diet ameliorates oxycodone-seeking behaviors in the absence of drug availability
and reduces anxiety. Guided by the major role gut microbiota have on brain function, neuropathology,
and anxiety, we profile the microbiome composition and the effects of chronic opioid exposure and n-3
PUFA supplementation. We demonstrate that the withdrawal of opioids led to a significant depletion
in specific microbiota genera, whereas n-3 PUFA supplementation increased microbial richness,
phylogenetic diversity, and evenness. Lastly, we examined the activation state of microglia in the
striatum and found that n-3 PUFA supplementation reduced the basal activation state of microglia.
These preclinical data suggest that a diet enriched in n-3 PUFAs could be used as a treatment to
alleviate anxiety induced opioid-seeking behavior and relapse in human opioid addiction.
Keywords: opioid; microbiome-brain axis; DHA; EPA; anxiety; polyunsaturated fatty acids;
Intravenous self-administration; mice
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1. Introduction
Several factors converged in the early 2000s to contribute to the escalating opioid epidemic.
These included an over-prescription of potent and synthetic opioids, a belief that chronic pain was
protective against the development of addictive behavior, an aggressive marketing strategy by the
manufacturers, and the incorrect translation that long-term use of extended release opioids, safe in
terminally-ill cancer patients, could be used in non-cancer patients without caution [1]. Alarming
statistics from recent years document the increase in mortality from the use of fentanyl and other
synthetic opioids that are often prescribed for pain [2–5]. For many of these cases, the initial exposure
to opioids began with oxycodone and other prescription analgesics, and was then transferred to other
more rapidly acting opioids [6]. We demonstrate in this paper that rapidly acting opioids are powerfully
reinforcing and that dietary supplementation of omega 3 polyunsaturated fatty acids (n-3 PUFAs) may
reduce the ability of these rapid-acting and potent compounds to maintain addictive-like behaviors via
action on gut microbiome composition.
Whichever the opioid, an inherent property of these addictive substances is the high rate (≈91%)
of relapse [7] and the relative lack of effective treatment [8]. The rate of relapse following chronic
opioid use has been linked to allostatic mechanisms that maintain persistent drug seeking such as
a decline in cognitive control over habituated behaviors and tolerance to drug effects over time.
The mechanisms that produce these long-lasting addictions are complex and can induce cravings that
lead to relapse months or years after the physical opioid dependence is no longer a factor. According
to the Impaired Response Inhibition and Salience Attribution (iRISA) model of addiction proposed
by Rita Goldstein and colleagues, the increased salience of drug-paired cues and impaired response
inhibition in the absence of the drug contribute to increased drug seeking over time and a persistence of
seeking in the absence of the drug [9–11]. These physical and emotional changes result in a persistent
negative emotional state culminating in an inability to transition to an opioid-free state and to remain
opioid-free [12]. Coupled with an increased vulnerability to stress and both physical and psychological
stressors that trigger drug use in drug addicted humans and animals [13], relapse after prior opioid
use is a common occurrence that must be addressed.
Several studies have focused on the bidirectional communication that takes place between the
gastrointestinal tract and the central nervous system (CNS). Previous studies have revealed the major
role gut microbiota have on brain function, and consequently, neuropathology [14–18]. Anxiogenic
affective-like behaviors are lower in mice that exhibit increases in specific genera, including Lactobacillus
and Bifidobacterium, and these changes were linked to altered neural function [19,20]. A similar
relationship between Bifidobacterium and anxiety in humans has been established [21]. Still, the role of
nutrition and supplementation in the microbiome-brain axis in psychiatry is not fully understood.
The family of n-3 PUFAs consists of docosahexaenoic acid (DHA; c22:6n-3), ecosapentaenoic acid
(EPA; c20:5n-3), both available from fish, and alpha-linolenic acid (ALA: c18; 3n-3), available from
plants. The beneficial effects of supplementary n-3 PUFAs for many conditions and diseases have been
the subject of ongoing research. A recurrent observation is that dietary omega-3 supplementation
relieves anxiety and depression symptoms in mood disorders often co-diagnosed in substance abuse
disorder patients (for reviews, see References [22–24]). Accordingly, n-3 PUFA supplements enriched
in DHA have been shown to reduce anxiogenic affective-like behaviors in preclinical models [22,25,26]
and clinical trials [23,27–31]. DHA and EPA have both shared independent anti-inflammatory
properties by intervening at different points within the inflammatory cascade, which provides an
important consideration for their translational benefits (reviewed in Calder [32]). DHA is also required
as a structural component of plasma, microsomal, and synaptic membranes in the brain [33,34],
and is essential for numerous brain functions including development [35] and diverse cellular
functions [36–40]. There is also evidence that n-3 PUFA supplementation influences the gut microbiota,
which can contribute to changes in brain function [41–43]. The overarching hypothesis for our study
was that n-3 PUFA intake induces a beneficial shift in gut microbiome composition to normalize the
genera that become overgrown with opioid-self administration.
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We have previously shown that chronic, noncontingent morphine induces diverse adaptations
of the glutamatergic system in the striatum, a hub of the reward-centered mesolimbic circuitry [44].
Many of these cellular and behavioral adaptations were reduced or offset by a PUFA-enriched diet.
The model of opioid exposure used in this previous study was an escalating dose of morphine,
administered over 5 days via subcutaneous injection twice daily, followed an additional 3 days of
morphine (at the highest dose), a noncontingent method of delivery. In the present study, we used
an opioid exposure model with greater predictive and face validity to mimic opioid use disorder.
This model uses contingent exposure whereby there is a choice as to how much opioid to self-administer
through an indwelling intravenous catheter. The delivery of each drug infusion was contingent on
pressing a designated active lever in an operant box. This allowed us to generate a 27-day profile of
opioid use in mice, equating to 3 years of a human life [45], beginning with the acquisition of this
behavior, followed by a period of maintenance, then periods of extinction alternating with reinstatement.
This profile of opioid self-administration arguably recapitulates that seen in humans, with initial opioid
use followed by alternating periods of abstinence and relapse. Using this model, we first outline this
opioid use profile and then asked to what extent an n-3-PUFA-enriched diet may alter drug-seeking
behaviors. We also assessed to what extent this supplementation had on affective-like behavior using
the light–dark test. We then examined how chronic opioid self-administration and the n-3 PUFA
supplementation, separately and in combination, altered gut microbiome composition. We achieved
this by examining the gut microbiome during multiple phases of the opioid exposure model. Lastly,
we examined the state of the microglia in the striatum, a site we had previously studied [43], at the
completion of the trial to determine whether there was evidence of altered microglial activation due to
the opioid exposure or n-3 PUFA supplementation.
2. Materials and Methods
All the experiments were conducted in accordance with the American Association for Laboratory
Animal Care (AALAC) Guide for the Care and Use of Laboratory Animals and approved by the
University of California Los Angeles (UCLA) Institutional Animal Care and Use Committee (IACUC
committee) (Office of Animal Research Oversight (OARO) #1999-179). Mice (C57Bl6/J Jax stock
# 000664), 6–8 weeks of age at the start of the experiment, were randomly assigned to a control lab
chow diet containing 0.5% DHA (control group) alone or supplemented with 2.5% DHA, 1.1% EPA,
and 0.75% other omega-3 PUFAs (Nordic Naturals, Watsonville, CA, USA) for 8 weeks (n-3 PUFA
group). We have previously shown an increase in DHA enrichment in specific brain regions in male,
but not female, C57Bl6/J mice following this same protocol [44]. Accordingly, only male C57Bl6/J mice
were used for these experiments. Of note is that as the PUFA supplementation protocol carried a strong
fish odor; as such, it was not possible for experimenters to remain blind to this intervention for the
behavioral procedures. However, experimenters were blind for all other procedures and data analyses.
2.1. Intravenous Self-Administration (IVSA) Administration
Mice were divided into four groups: control diet + saline (n = 14), control diet + opioid (n = 14),
n-3 PUFA diet + saline (n = 5), and n-3 PUFA diet + opioid (n = 10). An intravenous catheter (0.2 mm
i.d., 0.4 mm o.d., NorfolkAccess, Skokie, IL, USA) was inserted into the right jugular vein of mice under
sterile conditions, as we have previously described [46–48]. Post-operative care included Carprofen
gel food (MediGel CPF, Portland, ME, USA). Catheters were flushed daily with 0.02 mL Heparin/saline
(30 USP/mL). The overarching timeline of experiments is described in Figure 1. Mice were monitored
twice daily for the first 48 h after surgery and exclusion criteria of more than a 15% weight lost or a
moribund state for over 24 h were applied. Catheter patency was tested using an infusion of propofol
(20 µL of 1% propofol w/v in saline) every five days. After 3 days of postoperative recovery, mice
were trained to lever press in the self-administration operant boxes (Med-Associates Georgia, VT,
USA) by using a droplet of 20% sweetened condensed milk placed above both the active (AL) and
inactive (IAL) levers (3times per session) during the first two 120 min sessions. Mice underwent daily
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2-h self-administration sessions where the active lever was paired with remifentanil and an inactive
lever was paired with a saline infusion using a random lever-infusion assignment (Figure 1). An AL
press resulted in an intravenous drug infusion (0.67 µL/g body weight) and the presentation of a 10-s
tone and visual cue (light); together, these comprised a “reinforcer” (RNFS). A 10-s “timeout” period
followed each RNFS, during which time, no further RNFSs could be earned. The mice first underwent
a minimum of 3 days of acquisition training using remifentanil (0.05 mg/kg/infusion) as the delivered
opioid at a fixed ratio of one drug infusion for each lever press (FR1) to a maximum of 50 RNFS or
2 h, whichever came first (the acquisition phase). Once the criterion of 50 RNFS or 20% stability was
obtained for two consecutive days, the mice were transitioned to oxycodone (0.25 mg/kg/infusion)
under the same short-access 2-h FR1 schedule for 10 days (the maintenance phase). This was followed
by 5 days of extinction (1E), in which no further drug was delivered in response to an AL press but the
same environment and reward-associated cue conditions were presented; however, there was no limit
on the number of RNFSs that could be earned, with the session ending after 2 h. This was followed
by a 2-day period of reinstatement in which oxycodone was administered intravenously at the same
dose and cues as used during maintenance. Thereafter the mice underwent a second extinction for an
additional 5 days under the same conditions as during the first extinction with no limit on the number
of RNFSs that could be earned and the session ended after 2 h (2E). Due to the loss of catheter patency,
the number of mice in these later stages declined from those at the beginning of the experiment.
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Figure 1. A schematic of the experimental timeline that shows the type and order of interventions in
the 27-day protocol used for mice that had received an n-3 PUFA-enriched or control diet for 8 weeks
prior to the start of the protocol. Following the implant of the jugular catheter (IVSA surgery), mice
underwent daily sessions where, after acquisition of remifentanil self-administration, oxycodone
or saline infusion was self-administered for 10 days (the maintenance phase), followed by 5 days
of extinction (extinction 1, 1E), in which no further drug was delivered but the same environment
and reward-associated cues were presented. This was followed by a 2-day period of reinstate ent
(reinstate ent) in hich oxycodone as ad inistered at the sa e dose and cues as used during
aintenance. Thereafter the ice under ent a second extinction (extinction 2, 2E) over the follo ing
5 ays n er the same conditions as during 1E. Fecal boli were collected before the surgery and at each
change i this protocol as indicate . The lig t–dark (LD) test was conducted before the surgery and on
the second day of 2E. Brain tissue was collected at the end of the protocol for microglial analysis using
immunohistochemistry (IHC).
Statistical Analyses. The inter- and intra-session data were analyzed as a function of group
and time using a linear mixed model in R (R Core Team, 2015) using the package “lmerTest” [49].
The linear models were generated for each experimental group of interest. The models were used to
assess the effect of time, diet group, or an interaction of these factors on AL presses and RNFSs earned.
Whenever a significant effect was observed, a new reduced model was generated by removing the
significant factor and compared with the original model using an ANOVA in order to assess the impact
of the respective factor on the goodness-of-fit for the model. The resulting model was a regression
equation where the intercept was allowed to vary for each subject: YCharacteristic = β0 + βGroupXGroup ×
βTimeXTime + USubject, where YCharacteristic is the characteristic being modeled (e.g., active lever presses,
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reinforcers earned), each predictor variable is represented by its subscripted X, and USubject represents
the random effect of each individual subject. The coefficients (β) were estimated and assessed for
significance, and the contribution to the goodness of fit of the model was assessed.
2.2. Light–Dark Assay
The apparatus used for this test of anxiety-related behavior [50] consisted of light and dark
compartments of a square box (28 cm2 square 18 cm height) separated by a guillotine door in a quiet
room illuminated at 50–55 lux. The light compartment was illuminated at 1000 lux by a halogen
lamp, measured at the guillotine door. Mice (control diet, n = 7; n-3 PUFA diet, n = 7) were placed
in the dark compartment with the door closed for 2 min, after which, the guillotine door was raised
to allow free movement between the light and dark compartments for an additional 2 min. Video
tracking was recorded using a A1300-60gm Basler ace camera (106580-08, Basler, Germany), saved by
the downloadable VLC video software (VideoLAN), and analyzed for the time for a full body exit from
the dark compartment by experimenters blind to diet and opioid treatments.
Statistical Analysis. Data were analyzed using linear mixed models as previously described [49].
This test was conducted 3 days before insertion of the intravenous catheter and just before the operant
session on the second day of the second extinction period (25 days after the initial test).
2.3. Microbiome Characterization: 16S Ribosomal RNA Sequencing
Stool collection was done at the following time points: baseline (control diet, n = 5; n-3 PUFA diet,
n = 3), first day of oxycodone IVSA (control diet, n = 11; n-3 PUFA diet, n = 11), 10th day oxycodone
IVSA (control diet, n = 15; n-3 PUFA diet, n = 10), fifth day of first extinction (control diet, n = 15;
n-3 PUFA diet, n = 10), and the first day of the second extinction (control diet, n = 7; n-3 PUFA diet,
n = 7). Stool was collected a minimum of 30 min before any behavioral tests, including IVSA. Stool
was collected fresh and did not interact with any non-sterile surfaces. Mice were placed on top of a
cage (to provide them with something to hold onto), held gently at the base of their tails and massaged
until stool started to be naturally expelled. Once stool was partly exposed, sterile forceps were used to
remove the stool and place it into a sterile tube. Within 2 min of extraction, they were placed in an
−80 ◦C freezer and stored for 2–3 months prior to 16S rRNA sequencing. DNA was extracted from
frozen fecal pellets using the PowerSoil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA, USA)
with bead beating following the manufacturer’s instructions. The V4 region of 16S ribosomal RNA
genes was amplified and underwent 2 × 150 sequencing on an Illumina MiSeq (Illumina, San Diego,
CA, USA) as previously described [51]. The base pair reads were processed using QIIME v1.9.1 with
default parameters [52]. The sequence depth ranged from 47,843 to 128,236 sequences per sample.
Operational taxonomic units (OTUs) were picked against the May 2013 version of the Greengenes
database, pre-filtered at 97% identity. OTUs were removed if they were present in less than 10% of
samples. Alpha diversity (i.e., diversity within a sample) and beta diversity (differences in composition
across samples) were calculated in QIIME using OTU-level data rarefied to 47,843 sequences.
Statistical Analyses. The significance of differences in alpha diversity metrics—Faith’s phylogenetic
diversity (Faith’s PD), Chao1, and Shannon index—was calculated using analysis of variance.
Beta diversity was calculated using Bray-Curtis dissimilarity and visualized using principal coordinates
analysis. Adonis, a permutational analysis of variance, was performed using 100,000 permutations to
test for differences in distances across diet and groups [53,54]. Association of microbial genera with
diet and group (oxycodone and extinction phase) were evaluated using DESeq2 in R, which employs
an empirical Bayesian approach to shrink dispersion and fit non-rarified count data to a negative
binomial model [54]. It was seen that a few mice in the colony were affected by an overgrowth of
segmented filamentous bacteria (i.e., Candidatus Arthromitus). This species only contributed to less than
0.1% of the overall relative abundance, and because this represented a contaminant genus unrelated
to the experimental interventions, it was excluded from beta-diversity, alpha-diversity, and DESeq2
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analysis. The p-values for differential abundance were converted to q-values to correct for multiple
hypothesis testing (<0.05 for significance) [55].
2.4. IBA1 and CD68 Labeling
Brains from the four testing groups, including the control diet + saline (n = 2), control diet +
oxycodone (n = 2), n-3 PUFA diet + saline (n = 2), and n-3 PUFA diet + oxycodone (n = 5), were
collected 48 h after the last operant session. They were then placed in 4% paraformaldehyde overnight
at 4 ◦C, followed by 24–48 h in 30% sucrose until equilibrated, then frozen in a dry ice/isopropanol bath
and stored at −80 ◦C. Fifty micrometer sections were later cut and collected into phosphate buffered
saline (PBS), washed in PBS with 0.1% Triton X-100 (PBS-T; Sigma, city, MO, USA) 3 × 10 min each, and
blocked for 2 h at room temperature (RT) in 5% NGS + 3% BSA in PBS-T. They were then incubated
in the following antibodies diluted in the wash buffer; anti-rabbit IBA-1 (1:2000; Wako, Richmond,
VA, USA; cat. # 019-19741) and anti-mouse CD68 (1:1000; BioRad Hercule, CA, USA; cat. # MCA
1957) overnight at 4 ◦C. After another three washes for 10 min each, sections were incubated in the
following secondary antibodies; goat anti-rabbit 488 (1:1000) and goat anti-Rat 647 (1:1000; both from
Thermofisher, Waltham, MA, USA), diluted in PBS-T for 2 h at RT. After a final two washes in PBS-T and
one in PBS for 10 min at RT, the sections were mounted on Permamount slides and coverslipped with a
DAPI Antifade Mounting Medium (VectorLabs, Burlingame, CA, USA). A Leica DM5500 B upright
microscope with a Leica DFC9000 GT sCMOS camera and LAS X software (Lieica, Germany) and a
20× objective was used to obtain tiled images of each section. Sections (10 × 10”) from dorsomedial
and dorsolateral regions of the striatum were exported to ImageJ [56].
Statistical Analyses. The shape and intensity of CD68 labeled cells was quantified by a user blind
to the group identity with 5–30 cells quantified in each image and 5–10 images quantified for each of
the dorsolateral and dorsomedial striatal sections of each mouse, and as region had no effect, they
were combined into a single dataset for analysis using one-way ANOVA (Prizm v8).
3. Results
3.1. The Experimental Timeline
A schematic of the timeline used is shown in Figure 1 and described as follows. The basal
light–dark test and fecal collection occurred prior to the IVSA surgery, which was then followed by
the IVSA self-administration protocol consisting of five sequential phases; acquisition, maintenance,
extinction, reinstatement, and a second extinction. Fecal collection was performed between each
of these phases with the final light–dark test taking place on day 24 during the second extinction.
The experiment terminated with the collection of brain tissue on day 27 (Figure 1).
3.2. An n-3 PUFA-Enriched Diet Reduced Oxycodone-Seeking Behaviors
To both characterize the opioid self-administration profile and to assess the effect of an n-3
PUFA-enriched diet on this profile, mice maintained on a standard laboratory chow diet were
compared to mice given an increased level of n-3 PUFAs supplemented into the food. Both groups
of mice were trained to self-administer opioids in order to analyze drug-specific behaviors, the first
when remifentanil was self-administered (Figure S1A,B) and the second when oxycodone was
self-administered (Figure 2A–F).
Mice underwent at least three days of acquisition training using remifentanil as the delivered opioid
on an FR1 schedule. There was no effect of diet in the initial acquisition of opioid self-administration;
using remifentanil as the reinforcer, neither active lever presses (F(2,88) = 1.185, p = 0.3) nor reinforcers
(F(2,88) = 0.837, p = 0.44) were significantly different between the diet groups (Figure S1A,B).
The number of AL presses across this profile showed an effect of day (p < 0.001, χ2 = 12.147)
and diet (p < 0.05, χ2 = 4.646), as well as a significant day-by-diet interaction (p < 0.01, χ2 = 7.526).
For mice on the control diet, post-hoc analysis revealed an increase in AL pressing on 1E1 (p < 0.0001,
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χ2 = 21.367) and a decline in lever pressing thereafter during sessions 2E2–5 (p < 0.0001, χ2 = 31.481).
AL pressing during reinstatement did not differ from the last day of the first extinction period (1E),
but again increased on the first day of 2E following the 2-day reinstatement of oxycodone (R1 or R2
vs. 2E1; p < 0.01, χ2 = 7.164). For mice on the n-3 PUFA diet, post-hoc analysis showed an initial
similarity to those on the control diet with an increase in lever pressing on 1E1 (p < 0.01, χ2 = 10.583)
and a decline in lever pressing for each day of 1E thereafter (p < 0.0001, χ2 = 20.022). However, the
second extinction period following the two reinstatement sessions did not induce an increase in ALs.
Furthermore, AL pressing across sessions 2E1–5 by the n-3 PUFA mice was lower than that of the
control mice (p < 0.05, χ2 = 5.136) (Figure 2A). These results are consistent with the n-3 PUFA-enriched
diet reducing oxycodone seeking behaviors during the second but not first extinction period.
In assessing goal-directed lever pressing behavior, the number of inactive (no drug infusion)
lever presses showed significant day-by-diet interaction (p < 0.05, χ2 = 4.775); however, there was
no independent effect of diet, (p = 0.70, χ2 = 0.143) or day (p = 0.58, χ2 = 0.305) on this parameter
(Figure 2B). Goal-directed lever pressing behavior can also be evaluated by the percent of active
lever presses out of the total lever presses (AL/(AL + IAL)). This showed an effect of day (p < 0.0001,
χ2 = 19.231), but not diet (p = 0.67, χ2 = 0.178), nor any day-by-diet interaction (p = 0.69, χ2 = 0.156)
(Figure 2C).
A press on the AL followed by the delivery of oxycodone or saline, a tone and a 10-s visual
light cue, and a 10-s time-out period together comprised the reinforcer (RNFS). When measuring the
number of RNFSs earned, we found that this parameter mirrored the AL presses in that there was
a day (p < 0.01, χ2 = 10.361) and diet effect (p < 0.05, χ2 = 4.694), as well as a day-by-diet interaction
(p < 0.01, χ2 = 9.726). Further post-hoc analysis showed that, for mice on the control diet, the number of
RNFSs earned increased on 1E1 (p < 0.0001, χ2 = 16.547) and declined thereafter (p < 0.0001, χ2 = 25.288).
The number of RNFSs obtained during reinstatement did not differ from the last day of E1 and were
lower than the last day of maintenance (p < 0.01, χ2 = 10.538). However, there was an increase in
RNFSs earned on the first day of the second extinction period (2E1) above that of reinstatement (R1 vs.
2E1; p < 0.01, χ2 = 7.790). For mice on the n-3 PUFA diet, post-hoc analysis revealed an initial similarity
with those on the control diet, showing an increase in RNFSs earned on 1E1 (p < 0.0001, χ2 = 17.498)
and a decline in RNFSs for each day of 1E thereafter (p < 0.0001, χ2 = 20.478). However, the 2E1–5
sessions did not induce an increase in RNFSs earned when compared to the level observed during
reinstatement. Furthermore, the RNFSs earned by the n-3 PUFA mice across the five days of this 2E
period were lower than that of the control mice (p < 0.01, χ2 = 6.842) (Figure 2D).
Given our observation that the first day of 2E showed a clear protective effect for the n-3 PUFA
diet on opioid seeking behaviors, we then focused on the within-session behavior. Specifically, we
analyzed the rate of AL pressing or RNFSs earned within the 2-h access window on the first day of
2E. Using a mixed models linear analysis of these datasets, we found that the rate of AL pressing
showed an effect of diet (p < 0.05, χ2 = 3.889), time (p < 0.0001, χ2 = 30.788), and an interaction of diet
and time (p < 0.01, χ2 = 6.800) with the control group pressing more frequently than the n-3 PUFA
group (Figure 2E,F). Further in-depth analysis of the hourly data showed an effect of diet (p < 0.05,
χ2 = 4.018), but not time, on the frequency of AL pressing with the control group pressing more during
the first hour. During the second hour, the frequency of AL pressing declined, resulting in an effect of
time (p < 0.05, χ2 = 4.155), and a diet-by-time interaction (p < 0.05, χ2 = 4.884), but no effect of diet
alone (Figure 2E). In contrast, the rate of RNFSs earned did not show any clear effect of diet, time, nor
an interaction between the control and n-3 PUFA diet for the entire 2-h session. Post-hoc analysis of
each hour revealed no significant difference in RNFSs earned during the first hour. However, there
was an effect of diet (p < 0.01, χ2 = 7.254), time (p < 0.01, χ2 = 8.041), and a diet-by-time interaction
(p < 0.001, χ2 = 10.993) for the second hour. This was due to the rate of RNFSs earned by the n-3 PUFA
mice declining more rapidly than the control group during this hour (Figure 2F).
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Figure 2. An n-3 PUFA-enriched diet reduces oxycodone seeking behaviors. (A) Active lever presses.
Mice on both the control diet (black) and the n-3 PUFA-enriched diet (purple) showed an increase in AL
pressing on the first day of 1E (a; p < 0.0001) and a decline in lever pressing thereafter (b; p < 0.0001).
AL pressing during the reinstatement did not differ from the last day of 1E training or maintenance.
However, during 2E, there was an increase in lever pressing above that of the reinstatement (R1 or
R2 vs. 2E1; c; p < 0.01) for the control mice but not for the n-3 PUFA mice. Furthermore, active lever
pressing by the n-3 PUFA mice was lower than that of the control mice for all days of 2E (d; p < 0.05).
(B) Inactive lever presses. There was no effect of diet or day on this parameter. (C) Percent of active
lever presses. Although both saline groups showed ≤50% accuracy in AL presses as a percent of total
lever presses, this was not different from both opioid groups with ≥50% AL presses. (D) Reinforcers.
Control diet mice earned more RNFSs on 1E1 (a; p < 0.001) and this declined during the remaining
days of 1E (b; p < 0.0001). The number of RNFSs earned by the controls again increased above that of
the reinstatement during 2E (R1 or R2 vs. 2E1; c; p < 0.01). n-3 PUFA mice had a similar initial profile
as those on the control diet with an increase in RNFS earned on 2E1 (a; p < 0.0001), and a decline in
RNFS earned for each day of 1E thereafter (b; p < 0.0001). However, the 2E1–5 sessions did not induce
an increase in RNFSs earned from that seen during the reinstatement. (E) Active lever presses during
2E1. During the first hour of this session, the control mice pressed the AL more than the n-3 PUFA mice
(a; p < 0.05), and this rate declined during the second hour (b; p < 0.05). (F) Reinforcers during 2E1.
During the second but not the first hour, the number of RNFSs earned declined more rapidly in the n-3
PUFA mice than in the control mice (n-3 PUFA vs. control diet; c; p < 0.01, and an effect of time in n-3
PUFA but not control mice; d; p < 0.01). (G) Light–dark test. Although the n-3 PUFA intervention did
not alter the basal levels of anxiety, this diet did reduce anxiety, reflected as a quicker entry into the
light compartment from the dark compartment by the n-3 PUFA group on 2E2 (a; p < 0.05 vs. extinction
of the control mice).
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3.3. The n-3 PUFA-Enriched Diet Reduced Anxiety-Like Behavior during Extinction
We have previously shown that an n-3 PUFA-enriched diet reduces the anxiety state of mice
following chronic morphine [44]. Here we used the well-established light–dark test to repeatedly
assess the state of anxiety [50,57] (Figure 2G). Using linear regression analysis, we found that although
the n-3 PUFA diet did not alter the basal levels of anxiety (p = 0.4845, F(1,12) = −0.5203), the n-3
PUFA-enriched diet reduced anxiety-like behavior as assessed by decreased latency into the anxiogenic
light compartment (p < 0.05, F(1,12) = 7.027).
3.4. Microbiome Profiles Changed with an n-3 PUFA-Enriched Diet and with Opioid Extinction
We characterized the effect of n-3 PUFA on gut microbiome composition in the context of opioid
exposure by performing 16S rRNA sequencing of fecal samples collected from the two dietary groups at
baseline, during oxycodone maintenance (days 1 and 10), 1E, and 2E. There was a significant difference
in overall microbial composition between mice on the control diet and mice on the n-3 PUFA-enriched
diet (p-value < 0.05, R2 = 0.028) after adjusting for study phase (Figure 3A). There was also a significant
difference in the microbiome during the oxycodone maintenance phase as compared to both extinction
group periods (1E & 2E) while controlling for diet (p-value < 0.05, R2 = 0.10). There was no statistical
difference between microbiome profiles at day 1 (D1-OXY) of oxycodone maintenance and day 10
(D10-OXY). There was also no statistical difference in overall microbial composition between 1E and
2E. n-3 PUFA supplementation led to a significant increase in species richness measured using the
number of types of organisms (Chao1, p-value = 0.01), phylogenic diversity measured using the
evolutionary distance between organisms (Faith’s PD, p-value = 0.003), and species evenness measured
using the abundance of organisms across species (Shannon Index, p-value = 0.01)(Figure 3B). The mean
Bray–Curtis distances between groups were similar overall but it did show a trend, using PreOp as
a baseline, where the distance between mice on 10 days of oxycodone and a control diet was larger
than the distance between mice on 10 days of oxycodone and an omega-3 enriched diet (p-value = 0.1)
(Figure 3E).
Differential abundance testing was performed at the genus level to identify microbes that were
associated with n-3 PUFA supplementation during the oxycodone maintenance and opioid extinction
phases using DESeq2 models at a 5% false discovery rate threshold (q-value < 0.05). n-3 PUFA
supplementation led to a significant decrease during the oxycodone maintenance phase in Akkermansia
(4-fold) and Parabacteroides (5.5-fold), and a significant increase in multiple genera including Lactobacillus
(8-fold), Allobaculum (7-fold), and Bifidobacterium (7-fold) (Figure 4A). During the opioid extinction
phase, n-3 PUFA supplementation was similarly associated with the depletion of Parabacteroides
(3.4-fold) and enrichment of Bifidobacterium (8.5-fold), but Lactobacillus was not significantly different
and additional differences were observed, including increased Desulfovibrio (6-fold) (Figure 4B). Similar
analysis was then performed to identify genera associated with the opioid extinction phase compared
to the oxycodone maintenance phase in one or both diets. Opioid extinction led to a significant decrease
in Akkermansia (64-fold) and Bifidobacterium (8-fold), independent of diet. Opioid extinction also led to
a significant decrease in Parabacteroides (5-fold), but only within the control diet group (Figure 4C,D).
Lactobacillus did not significantly change with opioid extinction.
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Figure 3. n-3 PUFA supplementation and opioid extinction altered gut microbiome profiles.
(A) Principal coordinate analysis plot separated by diet and study phase (D1-OXY: Day 1 of oxycodone;
D10-OXY: Day 10 of oxycodone; 1E: First extinction phase, 2E: Second extinction phase). Each symbol
represents one fecal sample, with color denoting the dietary group and shape denoting the phase.
The axis labels indicate the percentage of variation represented by each coordinate. (B) Microbial
composition and diversity. Species richness (Chao1) (left), species evenness (Shannon Index) (middle),
and phylogenetic diversity (right) by diet (control diet in red and n-3-PUFA-enriched diet in blue).
(C) Phylum and (D) genus summary by groups. Bar plots show the average relative abundance of
microbes at the phylum and genus levels. D1-OXY and D10-OXY were combined, as were 1E and 2E.
(E) Bray–Curtis distances between groups.
Figure 4. Cont.
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Figure 4. Differential abundance of microbes differed by n-3 PUFA supplementation and opioid
extinction. (A) Effects of n-3 PUFA on genera abundance during oxycodone maintenance. DESeq2
models were used to identify differentially abundant genera (q < 0.05) in the n-3 PUFA supplementation
group, combining data from D1-OXY and D10-OXY and adjusting for the time point. Differences
are expressed as a log2 fold change, with the dot size proportional to the mean genera abundance
across samples and the dot color indicative of phylum. (B) Effects of n-3 PUFA on genera abundance
during opioid extinction found using DESeq2 analysis of combined 1E and 2E data, adjusted for phase.
(C) Effects of opioid extinction on genera abundance while on n-3 PUFA supplementation. (D) Effects
of opioid extinction on genera abundance while on a control diet.
3.5. The Activation State of Microglia was Affected by the n-3 PUFA-Enriched Diet but Not Opioid IVSA
To assess the activation state of microglia, we labeled these cells with two antibodies, one against
CD68, a lysosomal protein expressed in high levels in activated microglia [58], and one against IBA1,
a calcium binding protein found in microglia and macrophages [59]. This enabled us to count the
number of CD68-labeled microglia in the dorsomedial and dorsolateral striatum and then assess
the shape and density of IBA1 labeling in these CD68-positive cells. A representative slice image is
included in Figure 5A.
n-3 PUFA supplementation reduced the number of CD68+ cells as compared to the control diet
group (F(3,16) = 14.66, p < 0.001; one-way ANOVA), but opioid exposure did not induce any further
change (Figure 5B). We next analyzed cell morphology of the CD68+ cells. The cell area of the control
diet groups, whether saline or opioid-exposed groups, was lower than that of either n-3 PUFA control
(p < 0.001) or opioid-exposed (p < 0.05) groups (F(3,18) = 6.760, p = 0.003, one-way ANOVA). There was
no effect of opioid exposure following the control diet, but opioid exposure did lead to a decrease in
the cell area in the n-3 PUFA group (p < 0.05, n-3 PUFA saline vs. oxycodone) (Figure 5C). Next, we
measured the mean grey value or average pixel density of the CD68+ cells. This revealed a decrease in
mean density in the n-3 PUFA group compared to the control diet group, regardless of opioid exposure
(F(3,18) = 83.17, p < 0.001 in each diet group) (Figure 5D). However, there was no effect of opioid
self-administration in either diet group (p = 0.4 in each diet group) (Figure 5D). We then measured the
integrated density of CD68 immunolabeling by taking the sum of the pixels in the standardized selected
area within the dorsal striatum. This parameter was similarly altered by diet (F(3,18) = 38.42, p < 0.001),
with the n-3 PUFA group showing a significant decrease in integrated density (p < 0.001), but there
was no effect of opioid exposure (p = 0.95 and >0.9 in control and n-3 PUFA groups, respectively)
(Figure 5E).
Nutrients 2019, 11, 1900 12 of 18
Figure 5. The activation state of microglia was affected by the n-3 PUFA-enriched diet but not by the
oxycodone self-administration. To assess the activation state of microglia, the number of CD68-labeled
cells in the dorsomedial and dorsolateral striatum were counted and the shape and density of IBA1
labeling in these CD68+ cells was assessed. There was no effect of region on any of these parameters,
so the dorsomedial and dorsolateral data were combined. (A) A representative example of a coronal
section with CD68 labeled in red and IBA1 in green. An example of the dorsolateral region was enlarged,
with the arrows showing cells that were labeled with both the CD68 and IBA1 antibodies. (B) CD68.
The n-3 PUFA dietary regimen reduced the number of CD68+ cells compared to the control group
(***p < 0.001) but opioid IVSA did not induce any further change (*p < 0.05, n-3 PUFA oxycodone vs.
control oxycodone). (C) Cell area. The area of the cells of the controls, whether saline or opioid-treated,
was lower than that of the n-3 PUFA control (*** p < 0.001) or opioid-treated (* p < 0.05) groups.
The n-3 PUFA opioid-treated group did show a decrease in cell area compared with the n-3 control diet
group (p ≈ 0.05). (D) Mean grey value or average pixel density. This parameter showed an effect of
treatment with the n-3 PUFA groups, whether saline or opioid-treated, showing a lower pixel density
than the control groups (*** p < 0.001 in both groups). (E) Integrated density or the sum of the pixels
in the selected area. This parameter was similarly altered by treatment with an effect from n-3 PUFA
(*** p < 0.001), but no effect from opioid exposure.
4. Discussion
We have previously shown that an n-3 PUFA-enriched diet alters the behavioral and cellular
adaptations to non-contingent chronic morphine exposure [43]. In this study, we examined how this
same dietary regimen altered contingent opioid use. Our novel mouse model behavior paradigm
enabled us to assess the effect of volitional opioid exposure across a profile of opioid use that was
arguably closer to the human condition. In doing so, we generated a profile of opioid use that differs
from most IVSA studies published to date in that we focused on the drug-seeking behaviors during
a drug use cycle—extinction, reinstatement, and another period of extinction—to model the phases
of abstinence and relapse typical of opioid exposure. Interestingly, we found that oxycodone IVSA
established under a short-access FR1 schedule did not result in an increase in the number of active
lever presses or reinforcers gained above that of mice receiving saline during the initial maintenance
phase, possibly due to an inverted U-dose effect often seen in such studies [60]. However, during an
initial extinction period, when the drug was no longer available but all drug-associated cues were
present, there was a sharp increase in drug-seeking behaviors irrespective of diet during this first
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extinction. This drug-seeking declined over subsequent days to a level that was indistinguishable from
when the drug was again delivered during the reinstatement phase. The second extinction period
showed in the same increase in drug-seeking in the control group, but now the mice on the n-3 PUFA
diet failed to show this sharp increase in drug-seeking behavior, which was indistinguishable from
that of mice receiving the saline reinforcer.
Our previous study shows how this n-3-PUFA-enriched diet reduces the anxiogenic behavioral
profile induced by morphine and striatal glutamatergic signaling [43]. In this study we investigated
how this diet could modulate drug-seeking behaviors and the gut microbiome, knowing that there
was a microbiome–brain axis that modulates anxiety and depression (review by Foster and McVey
Neufeld [61]). We showed that the addition of n-3 PUFAs altered the gut microbiome during opioid
exposure and withdrawal, resulting in increased species richness, phylogenetic diversity, and evenness
compared to controls. Since dysbiosis (i.e., disease-associated perturbation of the microbiome) is
often associated with lower species richness and diversity, n-3 PUFA supplementation may protect
against adverse phenotypes mediated by the microbiome such as anxiety-like behavior. This effect is
similar to previously published studies examining the role of n-3 PUFA on the microbiome–brain axis.
For example, Robertson et al. showed that n-3 PUFA supplementation was associated with enhanced
cognition in C57BL/6 mice and an overabundance of Bifidobacterium [62]. A second study found
that n-3-PUFA-induced enrichment of Allobaculum was correlated with a reduction of anxiety-like
behavior [43]. Confirming these prior studies, we showed that n-3 PUFA supplementation was
associated with an increase in Bifidobacterium and Allobaculum. While the comparison of microbial
composition before and after opioid introduction was inconclusive, we did demonstrate a significant
reduction in Akkermansia and Bifidobacterium with opioid withdrawal. Interestingly, the addition of
n-3 PUFA during the extinction phase dampened the reduction of Bifidobacterium as compared to the
control. Prior research has shown that Bifidobacterium may increase the bioavailability of opioids by
deconjugating glucuronide in the gut lumen [63]. By having a higher level of deconjugating bacteria,
n-3 PUFA may ameliorate the effect of opioid extinction as compared to the control. However, the
effect of n-3 PUFA on the IVSA profile during the second extinction phase suggests that the reduction
in opioid-seeking was not the result of increased opioid bio-availability alone. One possibility is
that n-3-PUFA-induced Bifidobacterium and Lactobacillus reduced opioid-seeking behavior through
microbiome–brain signaling, consistent with literature demonstrating anxiolytic properties of specific
strains within these genera [20,64]. n-3 PUFA may also work by suppressing bacteria, such as
Akkermansia, that can induce anxiety-like behavior [65].
The underlying mechanism causing the increase in drug-seeking behaviors during the extinction
cycle is not completely understood and therefore it is also unclear how the n-3-PUFA-enriched diet led to
a decrease in these behaviors. Intuitively, it is assumed that the opioid-conditioned response is toward
the positive reinforcement associated with drug use; however, negative reinforcement mechanisms can
drive the compulsivity of drug addiction and relapse. The negative emotional state that is experienced
during drug abstinence following chronic opioid use and reinforcers paired with drug withdrawal
have been shown to lead to drug-seeking behaviors [66]. Studies in mice and humans suggest that an
elevated level of stress and anxiety increase the probability of relapse and that exposure to stressors
reliably reinstates drug-seeking behaviors even after prolonged drug-free periods. This negative
emotional state and the associated negative reinforcements may be the driving influence in our study
that led the control mice to increase their drug-seeking behaviors during the extinction phases of this
behavior paradigm. The reduction in drug-seeking behaviors due to the n-3 PUFA supplementation
corresponded to gut microbiome changes during opioid maintenance and withdrawal. The n-3 PUFA
supplementation could be playing a protective role in the gut microbiome by mitigating the microbiome
changes (i.e., the reduction in Bifidobacterium) observed due to opioid withdrawal during the extinction
phase. The n-3-PUFA-enriched diet also alleviated the anxiety-associated behaviors in the light–dark
test, which was induced by the opioid use and subsequent withdrawal during the extinction period.
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There is a strong possibility that the effect of n-3 PUFA supplementation seen in the gut microbiome
offset the increased levels of anxiety during the forced withdrawal period caused by extinction.
Intermittent noncontingent but not continuous morphine has been shown to alter the gut
microbiome and to induce neuro-inflammation. This can be offset by restoring the microbiome to
control levels [67]. Considering our findings that the n-3 PUFA diet altered the gut microbiome and offset
some of the opioid-induced changes seen during the second extinction phase, we hypothesized that the
n-3-PUFA-enriched diet would reduce microglial activation induced by oxycodone self-administration.
Assessing the size of the microglia, identified by the presence of CD68 labeling and the shape and
intensity of IBA-1 labelled CD68 cells, we found that this diet reduced the basal activation state of
microglia, shown as an increase in size and reduction in the number of cells and intensity of the
label. However, contrary to our hypothesis, there was little effect of oxycodone self-administration on
microglial activation. This may be a result of the low, continuous levels and relatively short access (2 h)
of opioid self-administered across the 27 days of the experiment, a regimen that is similar to continuous
opioid exposure [67] that may not induce measurable neuro-inflammation. The low sample number of
this experiment also warrants caution in furthering our interpretation of this dataset.
This study outlines a profile of opioid self-administration of an initial maintenance phase followed
by periods of abstinence, when drug-seeking became pronounced, and may imitate relapse. It was this
heightened period of drug-seeking that can be reduced by supplemental n-3 PUFA, which we also
show, reduced anxiety. We propose that such periods of opioid exposure and subsequent withdrawal
generate a long-term pathological state of anxiety that leads to the high rate of relapse associated with
opioid use and that this may be offset by n-3 PUFA supplementation. As n-3 PUFA has beneficial effects
on the gut microbiome, this PUFA may offset the effect of opioids on the gut–brain axis. The evidence
for this interaction between the gut microbiome and neuropathology continues to grow; we propose
that this may be the link by which n-3 PUFA offsets the cellular and behavioral effects of opioids, as
shown in this study and our previous work. Additional research does need to be completed in order to
understand whether affective-like behaviors and long-term drug-seeking behaviors could be treated by
normalizing the intestinal environment or by altering microbial function. Whichever the mechanism
involved, our findings do suggest that this supplemental dietary intervention could form part of a
treatment protocol for opioid use disorder.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/8/1900/s1,
Figure S1: The acquisition of remifentanil self-administration. (A) There was no effect of diet (control diet shown
in black, n-3 PUFA diet shown in purple) in the initial acquisition of opioid self-administration using remifentanil
as the RNFS when observing (A) AL presses (p = 0.3) or (B) RNFS earned (p = 0.4).
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